We established a retrospective cohort (cohort 1) of 106 patients with advanced NSCLC treated with a single-agent anti-PD-(L)1 as a second-line treatment (Supplementary Table 1)14. The gene discussed is CD274; the disease is non-small cell lung carcinoma.